These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
969 related items for PubMed ID: 28712074
1. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study. Weisler RH, Greenbaum M, Arnold V, Yu M, Yan B, Jaffee M, Robertson B. CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074 [Abstract] [Full Text] [Related]
2. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study. Brams M, Childress AC, Greenbaum M, Yu M, Yan B, Jaffee M, Robertson B. J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):19-28. PubMed ID: 28816509 [Abstract] [Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S. CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198 [Abstract] [Full Text] [Related]
4. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder. Mattingly G, Arnold V, Yan B, Yu M, Robertson B. J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468 [Abstract] [Full Text] [Related]
5. Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment. Wigal T, Childress A, Frick G, Yan B, Wigal S, Madhoo M. Postgrad Med; 2018 Jan; 130(1):111-121. PubMed ID: 29087231 [Abstract] [Full Text] [Related]
19. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. Nasser A, Hull JT, Chaturvedi SA, Liranso T, Odebo O, Kosheleff AR, Fry N, Cutler AJ, Rubin J, Schwabe S, Childress A. CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943 [Abstract] [Full Text] [Related]
20. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L. Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456 [Abstract] [Full Text] [Related] Page: [Next] [New Search]